Connection
Michael Birrer to Angiopoietin-2
This is a "connection" page, showing publications Michael Birrer has written about Angiopoietin-2.
|
|
Connection Strength |
|
|
|
|
|
0.157 |
|
|
|
-
Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, Dotan E, Makker V, Kaley T, Kuruvilla D, Gribbin M, McDevitt J, Lai DW, Dar M. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res. 2018 06 15; 24(12):2749-2757.
Score: 0.157